Engineering Animation, Inc. And EndoVascular Technologies, Inc. Bring The Power Of 3D Visualization To New Medical Procedures

January 06, 1997

EAI adds 3D imaging and diagnostic tools to EVT's system for repairing aortic aneurysms

AMES, Iowa--January 6, 1997--In a compelling blend of 3D graphics and medicine, Engineering Animation, Inc. (NASDAQ: EAII) is developing a software solution for EndoVascular Technologies, Inc. (NASDAQ: EVTI) that will initially be used to help revolutionize the treatment of unruptured abdominal aortic aneurysms (AAAs).

EAI's software will be used as a 3D visualization and diagnostic tool to guide the use of EVT's new Endovascular Grafting System (EGS System)--a less invasive, less costly alternative to open vascular surgery that should result in lower mortality, fewer complications, shorter hospital stays and quicker patient recoveries.

"EAI's software significantly reduces the time period from diagnosis to endovascular repair, providing expedited care for critical patients in need of immediate attention," said Jim Fitzsimmons, president and chief executive officer at EVT. "In addition, the software produces a computer-generated 3D model of the patient's internal anatomy, where aortic conditions can be better assessed and examined prior to treatment."

Software Furthers EVT's Breakthrough Medical Procedure
The EGS System, currently in Phase II FDA clinical trials, is a breakthrough alternative to traditional AAA surgery. Requiring only a small groin incision, the procedure involves transporting EVT's proprietary EndoGraft prosthesis to the aneurysm site in a delivery catheter. The prosthesis is implanted across the AAA--isolating it from blood flow and pressurization--thus preventing aneurysm expansion and minimizing the potential for rupture.

"EAI's experience using 3D visualization tools in sophisticated manufacturing, as well as scientific applications, complements EVT's mission to advance this alternative to open vascular surgery," said Fitzsimmons. "Software like this helps transform medical research into real-world medical applications."

The software enhances the process of evaluating patient eligibility for the procedure by automatically calculating key aortic measurements used to determine the correct type and size of graft needed by the patient. Doctors then verify these measurements, which is quicker and less tedious than previous methods of measuring and calculating the data by hand.

Advanced visualization technologies allow doctors to "fly through" a patient's aortic anatomy on the computer. Generated from the actual CT data, these realistic models provide a virtual environment where doctors can assess and determine a patient's condition without performing invasive procedures on the patient. The internal anatomy is automatically segmented by the computer, enabling doctors to identify structures and discern between pathology and healthy tissue.

"The computer images on the screen are just like opening up a patient and looking at their anatomy," said Fitzsimmons.

Important Advances For a Serious Cardiovascular Condition
AAAs are one of the most serious cardiovascular conditions, afflicting nearly 1.5 million people in the United States. This localized expansion of the aorta can rupture if left untreated, in most cases resulting in death. If an AAA is discovered, elective open surgery repair averages a morbidity rate of 15 percent to 40 percent.

"EAI is excited about incorporating our biomedical visualization and high-speed rendering technologies into EVT's new medical procedure," said Martin Vanderploeg, Ph.D., EAI's executive vice president and chief technology officer. "Our visualization solutions cut across many disciplines, and we are thrilled to be a part of medical history as EVT makes health care more affordable and comfortable for the patient."

About EAI
EAI specializes in applying 3D visualization technology to meet the productivity, communication, education and entertainment needs of its clients through three interrelated product lines: 3D visualization software, interactive multimedia and custom animation.

EAI's software products address the 3D visualization and digital prototyping needs of professionals in a wide range of industries. These high-speed, integrated 3D software products are used across the conceptual, design, analysis and manufacturing phases of product development.

EAI also uses 3D technology to develop interactive multimedia programs for clients in the consumer and educational markets. Completed CD-ROM titles include The Dynamic Human, CardioViewer 3D, The Dissectable Human and 3D Animation in the Courtroom. In addition to titles published on CD-ROM, EAI also produces custom interactive programs for corporations, museums, libraries, hospitals and universities.

The company's corporate headquarters and technology center are located in Ames, Iowa, with additional offices in Detroit, Chicago, Boston, Portland, Los Angeles, New York, Salt Lake City and Amsterdam.

About EVT
EndoVascular Technologies, Inc. designs, develops and manufacturers minimally invasive endovascular systems to repair diseased or damaged vascular structures. The company's Endovascular Grafting System or EGS System provides catheter-based delivery and implantation of a specialized, sutureless prosthesis to repair abdominal aortic aneurysms. The EGS system is designed to offer a minimally invasive alternative to the open surgical procedure performed today.

In the United States, EVT's Tube EGS System and Bifurcated EGSSystem are in Phase II clinical trials. Both products are also in clinical trials throughout Europe and have received marketing approval in Australia. The company's Aortoiliac EGS is also in a Phase II clinical trial in the United States, and European trials are targeted to begin in the first quarter of 1997.

Slides, videotape and electronic images are available from EAI upon request. For more information about EAI, visit us at

Engineering Animation, Inc.

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to